Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
meningococcal B rLP2086 vaccine candidate · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Immunization with one dose of MnB rLP2086 vaccine at 0, 1 and 6 months |
| Name | Type | Description |
|---|---|---|
| meningococcal B rLP2086 vaccine candidate | BIOLOGICAL | vaccine, 0.5 mL, 3 doses, 0 - 2 - 6 to 9 months |
| Blood draw | PROCEDURE | Blood draw |
Inclusion Criteria: * Healthy male or female subject between the ages of \>=18 and \<=40 years * Negative urine pregnancy test for all female subjects of childbearing potential prior to test article administration and at the completion of the study. * All female or male subjects who are biologicall...
The meningococcal B rLP2086 vaccine candidate is an investigational vaccine developed by Pfizer for the prevention of meningococcal B disease, including meningitis. It is designed to prompt an immune response against Neisseria meningitidis serogroup B. It has been studied in a Phase 1 clinical trial in healthy adult volunteers.
The meningococcal B rLP2086 vaccine candidate is being developed for the prevention of meningitis and meningococcal disease caused by serogroup B Neisseria meningitidis. It is intended for use in healthy individuals to reduce the risk of invasive meningococcal B infection. It remains investigational and is not an approved product.
Pfizer, Inc. (ticker PFE) is the developer of the meningococcal B rLP2086 vaccine candidate. Pfizer sponsored the Phase 1 clinical study of the vaccine conducted in Australia. The candidate is part of Pfizer's infectious disease vaccine pipeline.
The meningococcal B rLP2086 vaccine candidate is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. As an investigational vaccine candidate, it has not been approved by the FDA for any indication.
The meningococcal B rLP2086 vaccine candidate has been evaluated in one completed Phase 1 trial, NCT00780806, titled Safety And Blood Collection Study Of Meningococcal B Rlp2086 Vaccine In Adults. The trial enrolled 60 healthy adult volunteers aged 18 years and older in Australia and used a randomized, uncontrolled design.